Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy

被引：59

作者：

Bhargava-Shah, Aarohi ^{[1
]}

Foygel, Kira ^{[1
]}

Devulapally, Rammohan ^{[1
]}

Paulmurugan, Ramasamy ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Bio X Program, Mol Imaging Program Stanford, Palo Alto, CA 94304 USA

来源：

NANOMEDICINE | 2016年 / 11卷 / 03期

关键词：

anti-miR; cancer therapy; orlistat; PLGA nanoparticles; TNBC; FATTY-ACID SYNTHASE; POLYMER NANOPARTICLES; DRUG-DELIVERY; EXPRESSION; PROGRESSION; CARCINOMA; CELLS;

D O I：

10.2217/nnm.15.193

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Background: This study explores the use of hydrophilic poly(ethylene glycol)conjugated poly(lactic-co-glycolic acid) nanoparticles (PLGA-PEG-NPs) as delivery system to improve the antitumor effect of antiobesity drug orlistat for triple-negative breast cancer (TNBC) therapy by improving its bioavailability. Materials & methods: PLGA-PEG-NPs were synthesized by emulsion-diffusion-evaporation method, and the experiments were conducted in vitro in MDA-MB-231 and SKBr3 TNBC and normal breast fibroblast cells. Results: Delivery of orlistat via PLGA-PEG-NPs reduced its IC50 compared with free orlistat. Combined treatment of orlistat-loaded NPs and doxorubicin or antisense-miR-21-loaded NPs significantly enhanced apoptotic effect compared with independent doxorubicin, anti-miR-21-loaded NPs, orlistat-loaded NPs or free orlistat treatments. Conclusion: We demonstrate that orlistat in combination with antisense-miR-21 or current chemotherapy holds great promise as a novel and versatile treatment agent for TNBC.

引用

页码：235 / 247

页数：13

共 27 条

[1]

PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect [J].